Julie Earl

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers

Hans F. A. Vasen, Isaura S. Ibrahim, Carmen Guillén‐Ponce et al. · Journal of Clinical Oncology · 2016 · 338 citations · Full text

Medicine, Oncology, Pathology +17

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy

Cristina Balbás-Martínez, Ana Sagrera, Enrique Carrillo de Santa Pau et al. · Nature Genetics · 2013 · 291 citations · Full text

Medicine, Molecular Genetics, Oncology +9

Mosaic loss of chromosome Y is associated with common variation near TCL1A

Weiyin Zhou, Mitchell J. Machiela, Neal D. Freedman et al. · Nature Genetics · 2016 · 235 citations

Life Sciences, Genetics, Molecular Genetics +13

Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer

Julie Earl, Sandra García-Nieto, José Carlos Martínez Ávila et al. · BMC Cancer · 2015 · 178 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Enrique Grande, Jaume Capdevila, Daniel Castellano et al. · Annals of Oncology · 2015 · 157 citations · Full text

Medicine, Oncology, Pharmacology +13